-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Hold on ResMed, Lowers Price Target to $225

Benzinga·07/10/2026 18:32:57
Listen to the news
Jefferies analyst Matthew Taylor maintains ResMed (NYSE:RMD) with a Hold and lowers the price target from $240 to $225.